Skip to main content

Advertisement

SpringerLink
Log in

Prognostic Value of Tumor Regression Grade Based on Ryan Score in Squamous Cell Carcinoma and Adenocarcinoma of Esophagus

  • Thoracic Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Purposes

Tumor regression grade (TRG) of the primary tumor after neoadjuvant therapy is one of the most sensitive prognostic factors among patients with locally advanced esophageal cancer, although no TRG system is fully accepted. The Ryan score was proposed in 2005 to evaluate TRG in rectal cancer and could be adaptable for pathological evaluation of esophageal cancer. The objective of this study is to evaluate the prognostic value of the Ryan score for esophageal cancer in the setting of trimodal therapy.

Methods

We performed a retrospective cohort study in which patients with locally advanced esophageal cancer, submitted to neoadjuvant therapy followed by surgical resection, were selected. One hundred thirty-four patients were selected. All tissue specimens were assessed as per the TRG system proposed by Ryan et al. Survival curves were assessed by the Kaplan–Meier method and log-rank test. Chi-square test or likelihood-ratio test was used for absolute and relative variables. Kruskal–Wallis and analysis of variance tests were used to assess significant differences on a continuous dependent variable by a categorical independent variable.

Results

Of the 134 included patients, 94 (70.1%) had squamous cell carcinoma, and 40 (29.9%) adenocarcinoma. Ryan score was correlated with histological type (p < 0.001), and clinical (p = 0.044) and pathological (p < 0.001) staging. Mean follow-up was 31.1 months. Multivariate analysis showed that Ryan score can safely predict survival, and systemic and lymphatic recurrence (p < 0.05).

Conclusions

Ryan score is an effective system to evaluate TRG and can predict risk for lymph node or distant metastasis, overall survival, and disease-free survival.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074–84.

    Article  Google Scholar 

  2. Mota FC, Cecconello I, Takeda FR, Tustumi F, Sallum RAA, Bernardo WM. Neoadjuvant therapy or upfront surgery? A systematic review and meta-analysis of T2N0 esophageal cancer treatment options. Int J Surg. 2018;54(Pt A):176–81.

    Article  CAS  Google Scholar 

  3. Lerttanatum N, Tharavej C, Chongpison Y, Sanpavat A. Comparison of tumor regression grading system in locally advanced esophageal squamous cell carcinoma after preoperative radio-chemotherapy to determine the most accurate system predicting prognosis. J Gastrointest Oncol. 2019;10(2):276–82.

    Article  Google Scholar 

  4. Andreollo NA, Beraldo GC, Alves IPF, Tercioti-Junior V, Ferrer JAP, Coelho-Neto JS, et al. Pathologic complete response (ypT0 ypN0) after chemotherapy and radiotherapy neoadjuvant followed by esophagectomy in the squamous cell carcinoma of the esophagus. Arq Bras Cir Dig. 2018;31(4):e1405.

    Article  Google Scholar 

  5. Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer. 1994;73(11):2680–6.

    Article  CAS  Google Scholar 

  6. Chirieac LR, Swisher SG, Ajani JA, Komaki RR, Correa AM, Morris JS, et al. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer. 2005;103(7):1347–55.

    Article  Google Scholar 

  7. Schneider PM, Baldus SE, Metzger R, Kocher M, Bongartz R, Bollschweiler E, et al. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification. Ann Surg. 2005;242(5):684–92.

    Article  Google Scholar 

  8. Ryan R, Gibbons D, Hyland JM, Treanor D, White A, et al. Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Histopathology. 2005;47(2):141–6.

    Article  CAS  Google Scholar 

  9. Kim SH, Chang HJ, Kim DY, Park JW, Baek JY, Kim SY, et al. What is the ideal tumor regression grading system in rectal cancer patients after preoperative chemoradiotherapy? Cancer Res Treat. 2016;48(3):998–1009.

    Article  Google Scholar 

  10. Rice TW, Patil DT, Blackstone EH. 8th Edition AJCC/UICC Staging of cancers of the esophagus and esophagogastric junction: application to clinical practice. Ann Cardiothorac Surg. 2017;6(2):119–30.

    Article  Google Scholar 

  11. Takeda FR, Viyuela MS, da Cruz Junior JB, Tustumi F, Braghiroli OFM, Karolyne Ernesto Luiz Nobre KEL, et al. Variables associated to pathologic complete response, overall survival and disease-free survival in the neoadjuvant setting for esophageal cancer: a retrospective cohort analysis. Int Surg. 2018;103:214–21.

    Article  Google Scholar 

  12. Dubben HH, Thames HD, Beck-Bornholdt HP. Tumor volume: a basic and specific response predictor in radiotherapy. Radiother Oncol. 1998;47(2):167–74.

    Article  CAS  Google Scholar 

  13. Ji KSY, Thomas SM, Roman SA, Czito B, Anderson KL Jr, Frakes J, Adam MA, et al. Low- vs. high-dose neoadjuvant radiation in trimodality treatment of locally advanced esophageal cancer. J Gastrointest Surg. 2019;23(5):885–94. https://doi.org/10.1007/s11605-018-4007-3. Epub 2018 Oct 29.

    Article  Google Scholar 

  14. Buckstein M, Rhome R, Ru M, Moshier E. Neoadjuvant chemoradiation radiation dose levels for surgically resectable esophageal cancer: predictors of use and outcomes. Dis Esophagus. 2018;31(5).

  15. van der Werf LR, Dikken JL, van der Willik EM, van Berge Henegouwen MI, Nieuwenhuijzen GAP, Wijnhoven BPL; Dutch Upper Gastrointestinal Cancer Audit (DUCA) group. Time interval between neoadjuvant chemoradiotherapy and surgery for oesophageal or junctional cancer: a nationwide study. Eur J Cancer. 2018;91:76-85.

  16. Shapiro J, van Hagen P, Lingsma HF, Wijnhoven BP, Biermann K, ten Kate FJ, Steyerberg EW, van der Gaast A, van Lanschot JJ; CROSS Study Group. Prolonged time to surgery after neoadjuvant chemoradiotherapy increases histopathological response without affecting survival in patients with esophageal or junctional cancer. Ann Surg. 2014;260(5):807–13; discussion 813–4.

  17. Chiu CH, Chao YK, Chang HK, Tseng CK, Chan SC, Liu YH, Chen WH. Interval between neoadjuvant chemoradiotherapy and surgery for esophageal squamous cell carcinoma: does delayed surgery impact outcome? Ann Surg Oncol. 2013;20:4245–51.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Digestive Surgery Division, Department of Gastroenterology, University of São Paulo Medical School, São Paulo, SP, Brazil

    Flávio Roberto Takeda PhD, Francisco Tustumi MD, Carlos de Almeida Obregon MD, Gustavo Gonçalves Yogolare MD, Yasmin Peres Navarro MD, Rubens Antonio Aissar Sallum PhD, Ulysses Ribeiro Junior PhD & Ivan Cecconello PhD

  2. Division of Pathological Anatomy, Department of Pathology, University of São Paulo Medical School, São Paulo, SP, Brazil

    Vanderlei Segatelli MD

Authors
  1. Flávio Roberto Takeda PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Francisco Tustumi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Carlos de Almeida Obregon MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gustavo Gonçalves Yogolare MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yasmin Peres Navarro MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Vanderlei Segatelli MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Rubens Antonio Aissar Sallum PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ulysses Ribeiro Junior PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Ivan Cecconello PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Francisco Tustumi MD.

Ethics declarations

Disclosures

There are no relevant conflicts of interest or disclosures.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Takeda, F.R., Tustumi, F., de Almeida Obregon, C. et al. Prognostic Value of Tumor Regression Grade Based on Ryan Score in Squamous Cell Carcinoma and Adenocarcinoma of Esophagus. Ann Surg Oncol 27, 1241–1247 (2020). https://doi.org/10.1245/s10434-019-07967-8

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-019-07967-8

Search

Navigation